Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Equity (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Return on Equity for 4 consecutive years, with 4.36% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 178.0% to 4.36% in Q3 2025 year-over-year; TTM through Sep 2025 was 4.36%, a 178.0% decrease, with the full-year FY2024 number at 2.42%, down 143.0% from a year prior.
  • Return on Equity was 4.36% for Q3 2025 at bioAffinity Technologies, down from 33.55% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 33.55% in Q2 2025 to a low of 4.82% in Q1 2025.
  • A 4-year average of 0.84% and a median of 1.5% in 2023 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 3557bps in 2025; the steepest drop was -316bps in 2025.
  • bioAffinity Technologies' Return on Equity stood at 0.69% in 2022, then crashed by -94bps to 1.34% in 2023, then tumbled by -136bps to 3.16% in 2024, then crashed by -38bps to 4.36% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Return on Equity are 4.36% (Q3 2025), 33.55% (Q2 2025), and 4.82% (Q1 2025).